Servier to Acquire Exclusive Worldwide Rights of BioNova’s BN104, a potential best-in-class menin inhibitor
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutics for the patients we serve.
ONCOLOGY & Neurology
Smaller patient populations are not deterrents for Servier, we see each patient as a person who is desperately in need of new therapeutic options
39 Active Servier Oncology and Neurology Programs
24
Pre-Clinical
7
Phase 1
4
Phase 2
3
Phase 3
1
Filing
CAREER
See a future at Servier?
NEWSROOM
Latest Servier News
Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers
Shining a Light on Chondrosarcoma: A Rare Disease with Urgent Needs